Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
23
02
2022
accepted:
07
04
2022
revised:
05
04
2022
pubmed:
21
4
2022
medline:
7
6
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
There is long-standing interest in estimating non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) for AML, but existing tools have limited discriminative capacity. Using single-institution data from 861 adults with AML, we retrospectively examined the Treatment-Related Mortality (TRM) score, originally developed to predict early mortality following induction chemotherapy, as a predictor of post-HCT outcome. NRM risks increased stepwise across the four TRM score quartiles (at 3 years: 9% [95% confidence interval: 5-13%] in Q1 vs. 28% [22-34%] in Q4). The 3-year risk of relapse was lower in patients with lower TRM score (26% [20-32%] in Q1 vs. 37% [30-43%] in Q4). Consequently, relapse-free survival (RFS) and overall survival (OS) estimates progressively decreased (RFS at 3 years: 66% [59-72%] in Q1 vs. 36% [29-42%] in Q4; OS at 3 years: 72% [66-78%] in Q1 vs. 39% [33-46%] in Q4). With a C-statistic of 0.661 (continuous variable) or 0.642 (categorized by quartile), the TRM score predicted NRM better than the Pretransplantation Assessment of Mortality (PAM) score (0.603) or the HCT-CI/age composite score (0.576). While post-HCT outcome prediction remains challenging, these findings suggest that the TRM score may be useful for risk stratification for adults with AML undergoing allogeneic HCT.
Identifiants
pubmed: 35440690
doi: 10.1038/s41375-022-01574-5
pii: 10.1038/s41375-022-01574-5
pmc: PMC9177780
mid: NIHMS1796832
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1563-1574Subventions
Organisme : NCI NIH HHS
ID : P01 CA018029
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA078902
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579–90.
pubmed: 22949046
doi: 10.1038/nrclinonc.2012.150
Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127:62–70.
pubmed: 26660427
doi: 10.1182/blood-2015-07-604546
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
pubmed: 27895058
pmcid: 5291965
doi: 10.1182/blood-2016-08-733196
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.
pubmed: 15994282
pmcid: 1895304
doi: 10.1182/blood-2005-05-2004
Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110:4606–13.
pubmed: 17873123
pmcid: 2234788
doi: 10.1182/blood-2007-06-096966
Raimondi R, Tosetto A, Oneto R, Cavazzina R, Rodeghiero F, Bacigalupo A, et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. Blood. 2012;120:1327–33.
pubmed: 22740454
doi: 10.1182/blood-2012-03-414573
Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, et al. Prospective validation of the predictive power of the Hematopoietic Cell Transplantation Comorbidity Index: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2015;21:1479–87.
pubmed: 25862591
pmcid: 4512746
doi: 10.1016/j.bbmt.2015.04.004
Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med. 2006;144:407–14.
pubmed: 16549853
doi: 10.7326/0003-4819-144-6-200603210-00007
Au BKC, Gooley TA, Armand P, Fang M, Madtes DK, Sorror ML, et al. Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2015;21:848–54.
pubmed: 25644959
pmcid: 4408250
doi: 10.1016/j.bbmt.2015.01.011
Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47:749–56.
pubmed: 21643021
doi: 10.1038/bmt.2011.110
Hemmati PG, Terwey TH, le Coutre P, Vuong LG, Massenkeil G, Dörken B, et al. A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. Eur J Haematol. 2011;86:305–16.
pubmed: 21265883
doi: 10.1111/j.1600-0609.2011.01580.x
Barba P, Martino R, Pérez-Simón JA, Fernández-Avilés F, Castillo N, Piñana JL, et al. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:66–72.
pubmed: 24141006
doi: 10.1016/j.bbmt.2013.10.011
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
pubmed: 24744269
pmcid: 4047501
doi: 10.1182/blood-2014-01-552984
Yanada M, Konuma T, Mizuno S, Saburi M, Shinohara A, Tanaka M, et al. Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transplant. 2021;56:387–94.
pubmed: 32796950
doi: 10.1038/s41409-020-01032-9
Shouval R, Fein JA, Cho C, Avecilla ST, Ruiz J, Tomas AA, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6:1525–35.
pubmed: 34507354
pmcid: 8905694
doi: 10.1182/bloodadvances.2021004319
Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, et al. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3:1881–90.
pubmed: 31221661
pmcid: 6595255
doi: 10.1182/bloodadvances.2019032268
Al-Shaibani E, Cyriac S, Chen S, Lipton JH, Kim DD, Viswabandya A, et al. Comparison of the prognostic ability of the HCT-CI, the modified EBMT, and the EBMT-ADT pre-transplant risk scores for acute leukemia. Clin Lymphoma Myeloma Leuk. 2021;21:e559–e568.
pubmed: 33678592
doi: 10.1016/j.clml.2021.01.022
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417–23.
pubmed: 21969499
pmcid: 3221524
doi: 10.1200/JCO.2011.35.7525
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
pubmed: 27069254
doi: 10.1182/blood-2016-03-643544
Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:1190–7.
pubmed: 21282535
pmcid: 3083874
doi: 10.1200/JCO.2010.31.8121
Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813–21.
pubmed: 23847197
pmcid: 3765060
doi: 10.1182/blood-2013-06-506725
Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29:137–44.
pubmed: 24888275
doi: 10.1038/leu.2014.173
Walter RB, Sandmaier BM, Storer BE, Godwin CD, Buckley SA, Pagel JM, et al. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol Blood Marrow Transplant. 2015;21:373–8.
pubmed: 25278455
doi: 10.1016/j.bbmt.2014.09.022
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: is it time to move toward a minimal residual disease-based definition of complete remission. J Clin Oncol. 2016;34:329–36.
pubmed: 26668349
doi: 10.1200/JCO.2015.63.3826
Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, et al. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30:1456–64.
pubmed: 27012865
pmcid: 4935622
doi: 10.1038/leu.2016.46
Hoffmann AP, Besch AL, Othus M, Morsink LM, Wood BL, Mielcarek M, et al. Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Bone Marrow Transplant. 2020;55:669–72.
pubmed: 31685932
doi: 10.1038/s41409-019-0739-2
Morsink LM, Bezerra ED, Othus M, Wood BL, Fang M, Sandmaier BM, et al. Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia. 2020;34:1701–5.
pubmed: 31796913
doi: 10.1038/s41375-019-0671-x
Morsink LM, Othus M, Bezerra ED, Wood BL, Fang M, Sandmaier BM, et al. Impact of pre-transplant measurable residual disease on outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. Leukemia. 2020;34:1577–87.
pubmed: 31974434
pmcid: 7272254
doi: 10.1038/s41375-020-0717-0
Morsink LM, Sandmaier BM, Othus M, Palmieri R, Granot N, Bezerra ED, et al. Conditioning intensity, pre-transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Cancers. 2020;12:2339.
Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022;139:1694–706.
pubmed: 34995355
doi: 10.1182/blood.2021014804
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.
pubmed: 20385793
doi: 10.1182/blood-2009-11-254441
Breems DA, Van Putten WLJ, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KBJ, Mellink CHM, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791–7.
pubmed: 18695255
doi: 10.1200/JCO.2008.16.0259
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
pubmed: 7165009
doi: 10.1097/00000421-198212000-00014
Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249–56.
pubmed: 25154831
pmcid: 4178523
doi: 10.1200/JCO.2013.53.8157
Michelis FV, Messner HA, Uhm J, Alam N, Lambie A, McGillis L, et al. Modified EBMT pretransplant risk score can identify favorable-risk patients undergoing allogeneic hematopoietic cell transplantation for AML, not identified by the HCT-CI score. Clin Lymphoma Myeloma Leuk. 2015;15:e73–81.
pubmed: 25458081
doi: 10.1016/j.clml.2014.09.014
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2009;15:367–9.
pubmed: 19203728
pmcid: 3110087
doi: 10.1016/j.bbmt.2008.12.497
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.
pubmed: 19896087
pmcid: 2861656
doi: 10.1016/j.bbmt.2009.07.004
Wood BL. Acute myeloid leukemia minimal residual disease detection: the difference from normal approach. Curr Protoc Cytom. 2020;93:e73.
pubmed: 32311834
Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92:965–70.
doi: 10.1093/biomet/92.4.965
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.
pubmed: 21105791
pmcid: 3017343
doi: 10.1056/NEJMoa1004383
McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality After allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts. Ann Intern Med. 2020;172:229–39.
pubmed: 31958813
pmcid: 7847247
doi: 10.7326/M19-2936
Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, et al. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades. Haematologica. 2021;106:1599–607.
pubmed: 32499241
doi: 10.3324/haematol.2020.248187
Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, et al. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Leukemia. 2017;31:2560–7.
pubmed: 28555084
pmcid: 5709258
doi: 10.1038/leu.2017.165
Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, et al. Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica. 2018;103:e106–e109.
pubmed: 29242304
pmcid: 5830380
doi: 10.3324/haematol.2017.182642
Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MEM, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 2018;32:2352–62.
pubmed: 29720734
pmcid: 6192860
doi: 10.1038/s41375-018-0135-8
Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MEM, et al. Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. Haematologica. 2019;104:e143–e146.
pubmed: 30409798
pmcid: 6442971
doi: 10.3324/haematol.2018.204792
Mabrey FL, Gardner KM, Shannon Dorcy K, Perdue A, Smith HA, Davis AM, et al. Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Adv. 2020;4:611–6.
pubmed: 32074276
pmcid: 7042997
doi: 10.1182/bloodadvances.2019000707